Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients

NCT03976076 is registered in ClinicalTrials.gov with Bio-Pharm Solutions Co., Ltd. as lead sponsor.

NCT NCT03976076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03976076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
Lead sponsor
Bio-Pharm Solutions Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
April 15, 2020
Completion date
December 10, 2021
Enrollment
16 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

refractory infantile spasms